(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 1.94% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Novartis Ag's revenue in 2025 is $53,222,000,000.On average, 4 Wall Street analysts forecast NVS's revenue for 2025 to be $106,545,487,885,200, with the lowest NVS revenue forecast at $101,914,948,800,000, and the highest NVS revenue forecast at $110,711,735,568,000. On average, 4 Wall Street analysts forecast NVS's revenue for 2026 to be $108,449,533,665,900, with the lowest NVS revenue forecast at $103,245,313,500,000, and the highest NVS revenue forecast at $114,535,505,448,000.
In 2027, NVS is forecast to generate $110,472,052,439,700 in revenue, with the lowest revenue forecast at $107,013,047,400,000 and the highest revenue forecast at $112,970,996,560,800.